8-K 1 tm201887-1_8k.htm FORM 8-K












Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): January 13, 2020


Millendo Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-35890   45-1472564
(State or other jurisdiction
of incorporation)
File Number)
  (IRS Employer
Identification No.)


301 North Main Street, Suite 100
Ann Arbor, Michigan
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (734) 845-9000



(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange
on which registered

Common Stock, $0.001 par value per share




The Nasdaq Capital Market, LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company  ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨






Item 2.02.Results of Operations and Financial Condition.


As discussed below, on January 13, 2020, Millendo Therapeutics, Inc. (the “Company”) posted an updated corporate presentation (the “Corporate Presentation”) to its website at www.millendo.com. In the Corporate Presentation, the Company disclosed its estimated cash, cash equivalents and restricted cash balance of $63.5 million as of December 31, 2019. This amount is unaudited and preliminary, and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2019. The review of the Company’s financial statements for the year ended December 31, 2019 is ongoing and could result in changes to this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.


A copy of the Corporate Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 8.01Other Events.


On January 13, 2020, the Company updated its Corporate Presentation that it intends to use in connection with its presentations at conferences and in meetings with investors.


A copy of the Corporate Presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.


Item 9.01Financial Statements and Exhibits.


(d)    Exhibits


99.1   Corporate Presentation dated January 13, 2020






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 13, 2020 By:  /s/ Julia C. Owens, Ph.D.
    Julia C. Owens, Ph.D.
    President and Chief Executive Officer